Navigation Links
Targeting evolution: Could this be the next strategy to stop superbugs?
Date:11/6/2013

PHILADELPHIA A Penn Medicine researcher is among the winners of a GlaxoSmithKline (GSK) "academic drug hunter" competition that will help fast track his lab's work to stop drug-resistant bacteria.

"Superbugs" are evolving faster than antibiotics can keep up with, and as a result more than 2 million people in the United States get infected every year, and at least 23,000 people die as a direct result.

With this new partnership, Rahul Kohli, MD, PhD, an assistant professor in the division of Infectious Diseases and department of Biochemistry and Biophysics at the Perelman School of Medicine at the University of Pennsylvania, and his lab can ramp up their efforts to discover drugs that stop the evolution in its tracks. Rather than taking the conventional approach of modifying existing antibiotics to overcome resistance, Kohli's lab aims to target the very pathways by which bacteria adapt to antibiotics and evolve resistance.

Kohli's team, spearheaded by Charlie Mo, a graduate student in Biochemistry and Molecular Biophysics, will now have access to 1.8 million compounds kept in GSK's chemical library and their other drug discovery technologies.

"The search is on to find a molecule that can disrupt the pathway that allows bacteria to acquire drug resistance," Kohli said. "The hope is that such a molecule can make bacteria more sensitive to existing antibiotics or slow the acquisition to the resistance, both of which would be valuable in the clinic."

This is GSK's first Discovery Fast Track competition in North America, which is designed to translate academic research into starting points for new potential medicines. There were eight winners in total across the country, selected from an initial pool of over 140 applications across 17 therapeutic areas and from 70 different institutions.

The competition was sponsored by GSK's Discovery Partnership with Academia program, a new approach to drug discovery where academic partners become core members of drug-hunting teams. GSK and the academic partner share the risk and reward of innovation: GSK funds activities in the partner laboratories and provides in-kind resources to progress a program from an idea to a candidate medicine.

"We were extremely pleased to be recognized," Kohli said. "Now we can take an idea that has good potential and efficiently move it from a theoretical academic pursuit into the practical realm, where it can hopefully ultimately benefit patients."

Work on the winning Discovery Fast Track projects will begin immediately and the first screens are expected to be completed in mid-2014. Kohli expects results from his investigation shortly thereafter.


'/>"/>

Contact: Steve Graff
stephen.graff@uphs.upenn.edu
215-349-5653
University of Pennsylvania School of Medicine
Source:Eurekalert  

Related biology news :

1. Targeting cancers sweet tooth
2. Honey bee gene targeting offers system to understand food-related behavior
3. U of M researchers develop model for better testing, targeting of MPNST
4. Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
5. Signalling pathways meeting targeting the HER/EGFR family: Focus on breast, lung and colorectal cancers
6. Research improving breast cancer treatment by targeting tumor initiating cells
7. Cancer Cell article shows first evidence for targeting of Pol I as new approach to cancer therapy
8. Targeting tuberculosis hotspots could have widespread benefit
9. Nanobubbles plus chemotherapy equals single-cell cancer targeting
10. Climate change and coevolution: Weve done the math
11. Breakthrough by Temple researchers could lead to new treatment for heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Targeting evolution: Could this be the next strategy to stop superbugs?
(Date:2/24/2017)... BARCELONA, Spain , Feb. 24, 2017  EyeLock LLC, ... will demonstrate its elite iris biometric solution on ... with X16 LTE at Mobile World Congress ... in Qualcomm,s Booth in Hall 3, Stand ... contains the Qualcomm Haven™ security platform—a combination ...
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... 27, 2017 A Europe-wide survey of institutes ... using animals in their research treat them with due care. The ... detailed analysis of the results indicates that there is a strong ... put into practice the principles of the 3Rs (Refine, Reduce, ... What are ...
(Date:2/27/2017)... REDWOOD CITY, Calif. , Feb. 27, 2017 ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced today the U.S. Food ... New Drug Application (NDA) under section 505(b)(2) for ... for the treatment of patients with moderate-to-severe acute ...
(Date:2/27/2017)... HAMILTON, Bermuda , Feb. 27, 2017 /PRNewswire/ ... ) and SELLAS Life Sciences Group , ... immunotherapies, today announced that Advaxis has granted SELLAS ... agent using Advaxis, proprietary Lm -based antigen ... peptide antigen mixture (galinpepimut-S). Advaxis, ...
(Date:2/27/2017)... URBANDALE, Iowa (PRWEB) , ... February 27, 2017 , ... ... is following the advice of his grandfather, “Hire for attitude. Train for skill.” , ... State University star linebacker Jevohn Miller as a salesman. Zamzow is hoping to replicate ...
Breaking Biology Technology: